stockrowInhibikase Therapeutics, Inc.
IKTInhibikase Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $260,500.00, up 111.1% from fiscal 2022.
- EPS
- 0.00%
- Free cash flow
- −123.2%
Quarter to June 2026, against a year earlier
Follow IKT
Alert me
Inhibikase Therapeutics, Inc. (IKT) EV/Sales
As of 6 November 2026, Inhibikase Therapeutics, Inc. (IKT) trades at a EV/Sales of 395×. Over the past ten years it has ranged from −243× (November 2022) to 1,078× (September 2026); the current reading is higher than 89% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | −20.1× | — |
| FY2022 | −75.5× | — |
| FY2021 | −4.5× | — |
| FY2020 | 61.9× | (41.38%) |
| FY2019 | 106× | 0.00% |
| FY2018 | 106× | 0.00% |
| FY2017 | 106× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2023 | −20.1× | — |
| Sep 2023 | −25.7× | — |
| Jun 2023 | 5.2× | — |
| Mar 2023 | −53.6× | — |
| 13 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| DRUG Bright Minds Biosciences Inc. compare | n/m |
| ARTV Artiva Biotherapeutics, Inc. compare | n/m |
| PLX Protalix BioTherapeutics, Inc. compare | 2.3× |
| RNAC Cartesian Therapeutics, Inc. compare | 77.4× |
| SLGL Sol-Gel Technologies Ltd. compare | 121× |
| PALI Palisade Bio, Inc. compare | 151× |
| IKT Inhibikase Therapeutics, Inc. | 395× |
| IFRX InflaRx N.V. compare | 1,845× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)